CSPC Pharmaceutical Group Ltd (CHPTY) Lifted to “Buy” at Zacks Investment Research

CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a report released on Monday. The firm presently has a $82.00 target price on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 2.45% from the company’s current price.

According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “

Shares of CSPC Pharmaceutical Group (CHPTY) traded up 9.24% during midday trading on Monday, reaching $80.04. The company had a trading volume of 43 shares. The company’s 50 day moving average price is $77.14 and its 200-day moving average price is $71.24. The company has a market capitalization of $9.69 billion and a P/E ratio of 32.02. CSPC Pharmaceutical Group has a 52 week low of $51.03 and a 52 week high of $80.04.

WARNING: “CSPC Pharmaceutical Group Ltd (CHPTY) Lifted to “Buy” at Zacks Investment Research” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/09/cspc-pharmaceutical-group-ltd-chpty-lifted-to-buy-at-zacks-investment-research.html.

CSPC Pharmaceutical Group Company Profile

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceut

According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “

Shares of CSPC Pharmaceutical Group (CHPTY) traded up 9.24% during midday trading on Monday, reaching $80.04. The company had a trading volume of 43 shares. The company’s 50 day moving average price is $77.14 and its 200-day moving average price is $71.24. The company has a market capitalization of $9.69 billion and a P/E ratio of 32.02. CSPC Pharmaceutical Group has a 52 week low of $51.03 and a 52 week high of $80.04.

WARNING: “CSPC Pharmaceutical Group Ltd (CHPTY) Lifted to “Buy” at Zacks Investment Research” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/09/cspc-pharmaceutical-group-ltd-chpty-lifted-to-buy-at-zacks-investment-research.html.

CSPC Pharmaceutical Group Company Profile

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).

Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply